Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study
Frans J. Th. Wackers(Yale University), Lawrence H. Young(Yale University), Silvio E. Inzucchi(Yale University), Steven D. Wittlin(University of Rochester), Janice A. Davey(Yale University), Raymond Taillefer(Université de Montréal), Eugene J. Barrett(University of Virginia Health System), Neil Filipchuk, Robert E. Ratner, Ami E. Iskandrian(AstraZeneca (United Kingdom)), Deborah Chyun(Centre for Nursing Innovation), Gary V. Heller(Institute for Community Living)
Cited by 137
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
|Diabetes Care|2012|3.2k